Kieran F Geoghegan

List of Publications by Year
in descending order

60	5,037	172457	133252
papers	citations	29 h-index	59 g-index

62	62	62	6299
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models. EBioMedicine, 2018, 31, 122-132.	6.1	99
2	Emerging Methods in Chemoproteomics with Relevance to Drug Discovery. Methods in Molecular Biology, 2017, 1513, 11-22.	0.9	20
3	Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biology, 2017, 15, e2001882.	5.6	104
4	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. Scientific Reports, 2016, 6, 30859.	3.3	36
5	Modification of Amino Groups. Current Protocols in Protein Science, 2016, 86, 15.2.1-15.2.20.	2.8	4
6	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chemical Biology, 2016, 11, 3442-3451.	3.4	127
7	A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry. Rapid Communications in Mass Spectrometry, 2015, 29, 2175-2183.	1.5	11
8	Rational Targeting of Active-Site Tyrosine Residues Using Sulfonyl Fluoride Probes. ACS Chemical Biology, 2015, 10, 1094-1098.	3.4	153
9	Direct photocapture of bromodomains using tropolone chemical probes. MedChemComm, 2015, 6, 1018-1023.	3.4	9
10	A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS. Molecular BioSystems, 2015, 11, 2709-2712.	2.9	11
11	Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1414-22.	7.1	68
12	MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1. ACS Chemical Biology, 2015, 10, 2667-2671.	3.4	12
13	Chemoproteomics Demonstrates Target Engagement and Exquisite Selectivity of the Clinical Phosphodiesterase 10A Inhibitor MP-10 in Its Native Environment. ACS Chemical Biology, 2014, 9, 2823-2832.	3.4	22
14	Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. MedChemComm, 2014, 5, 1871-1878.	3.4	10
15	A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity. Analytical Biochemistry, 2014, 450, 63-69.	2.4	5
16	Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from Opposite Poles by Different Molecular Mechanisms. Structure, 2014, 22, 1161-1172.	3.3	159
17	Investigating Î³-secretase protein interactions in live cells using active site-directed clickable dual-photoaffinity probes. MedChemComm, 2014, 5, 321-327.	3.4	7
18	Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line. Protein Expression and Purification, 2013, 87, 27-34.	1.3	11

#	Article	IF	Citations
19	Chemoproteomic Analysis of Intertissue and Interspecies Isoform Diversity of AMP-activated Protein Kinase (AMPK). Journal of Biological Chemistry, 2013, 288, 35904-35912.	3.4	46
20	Deconstruction of Activity-Dependent Covalent Modification of Heme in Human Neutrophil Myeloperoxidase by Multistage Mass Spectrometry (MS⁴). Biochemistry, 2012, 51, 2065-2077.	2.5	20
21	Distinctive Attributes of Î²-Lactam Target Proteins in Acinetobacter baumannii Relevant to Development of New Antibiotics. Journal of the American Chemical Society, 2011, 133, 20536-20545.	13.7	85
22	Initiation of translation at an upstream non-AUG codon accounting for N-terminally extended minor forms of recombinant proteins expressed in insect cells. Protein Expression and Purification, 2011, 76, 72-78.	1.3	4
23	Pharmacodynamics and Pharmacokinetics of the Î³-Secretase Inhibitor PF-3084014. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 269-277.	2.5	52
24	Escherichia coli expression, purification and characterization of functional full-length recombinant Î±2Î²2Î³3 heterotrimeric complex of human AMP-activated protein kinase. Protein Expression and Purification, 2010, 73, 189-197.	1.3	21
25	Chemical Proteomic Technologies for Drug Target Identification. Annual Reports in Medicinal Chemistry, 2010, , 345-360.	0.9	9
26	Binding to the Low-Density Lipoprotein Receptor Accelerates Futile Catalytic Cycling in PCSK9 and Raises the Equilibrium Level of Intramolecular Acylenzyme. Biochemistry, 2009, 48, 2941-2949.	2.5	5
27	Modification of amyloid-Î²(1â€“40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-Î²(1â€“42). Analytical Biochemistry, 2008, 382, 147-149.	2.4	7
28	Biophysical and Biochemical Approach to Locating an Inhibitor Binding Site on Cholesteryl Ester Transfer Protein. Bioconjugate Chemistry, 2008, 19, 1604-1613.	3.6	13
29	Dominance of Amyloid Precursor Protein Sequence over Host Cell Secretases in Determining Î²-Amyloid Profiles Studies of Interspecies Variation and Drug Action by Internally Standardized Immunoprecipitation/Mass Spectrometry. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1144-1152.	2.5	22
30	Expression and protein chemistry yielding crystallization of the catalytic domain of ADAM17 complexed with a hydroxamate inhibitor. Protein Expression and Purification, 2007, 52, 313-319.	1.3	5
31	Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Structural and Molecular Biology, 2007, 14, 106-113.	8.2	238
32	Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nature Structural and Molecular Biology, 2007, 14, 413-419.	8.2	378
33	The 2.0 Ã... crystal structure of the ERÎ± ligand-binding domain complexed with lasofoxifene. Protein Science, 2007, 16, 897-905.	7.6	54
34	Concentration-Dependent Modulation of Amyloid-Î² in Vivo and in Vitro Using the Î³-Secretase Inhibitor, LY-450139. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 924-933.	2.5	127
35	Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Mass Spectrometry Reviews, 2005, 24, 347-366.	5.4	74
36	Tandem mass spectrometry of multiply phosphorylated forms of a ?histidine-tag? derived from a recombinant protein kinase expressed in bacteria. Rapid Communications in Mass Spectrometry, 2005, 19, 547-551.	1.5	6

#	Article	IF	Citations
37	Phosphorylation of serine residues in histidine-tag sequences attached to recombinant protein kinases: A cause of heterogeneity in mass and complications in function. Protein Expression and Purification, 2005, 44, 121-129.	1.3	22
38	A Thermally Sensitive Loop in Clostridial Glutamate Dehydrogenase Detected by Limited Proteolysis. Journal of Biological Chemistry, 2003, 278, 1067-1074.	3.4	13
39	Glutathione S-Transferase Omega 1-1 Is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interleukin-1à" Posttranslational Processing. Journal of Biological Chemistry, 2003, 278, 16567-16578.	3.4	180
40	Kinetic analysis of estrogen receptor/ligand interactions. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8562-8567.	7.1	210
41	Synthesis and biological activity of selective pipecolic acid-based TNF-Î± converting enzyme (TACE) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1387-1390.	2.2	76
42	Chemical and Biochemical Issues Related to X-ray Crystallography of the Ligand-Binding Domain of Estrogen Receptor Î±. Bioconjugate Chemistry, 2001, 12, 406-413.	3.6	12
43	Identification, Characterization, and Crystal Structure of the Omega Class Glutathione Transferases. Journal of Biological Chemistry, 2000, 275, 24798-24806.	3.4	625
44	Dye-Pair Reporter Systems for Proteinâ^'Peptide Molecular Interactions. Bioconjugate Chemistry, 2000, 11, 71-77.	3.6	29
45	Spontaneous Î±-N-6-Phosphogluconoylation of a â€œHis Tagâ€•inEscherichia coli:The Cause of Extra Mass of 258 or 178 Da in Fusion Proteins. Analytical Biochemistry, 1999, 267, 169-184.	2.4	190
46	32 Probing the stability of the tertiary structure of glutamate dehydrogenase by limited proteolysis. Biochemical Society Transactions, 1998, 26, S26-S26.	3.4	1
47	Modification of Amino Groups. Current Protocols in Protein Science, 1996, 4, Unit15.2.	2.8	5
48	Improved Method for Converting an Unmodified Peptide to an Energy-Transfer Substrate for a Proteinase. Bioconjugate Chemistry, 1996, 7, 385-391.	3.6	19
49	Selective Sequencing of Peptides with N-Terminal Ser or Thr in Mixtures. Techniques in Protein Chemistry, 1994, , 151-158.	0.3	0
50	Site-directed double fluorescent tagging of human renin and collagenase (MMP-1) substrate peptides using the periodate oxidation of N-terminal serine. An apparently general strategy for provision of energy-transfer substrates for proteases. Bioconjugate Chemistry, 1993, 4, 537-544.	3.6	37
51	Structural basis of latency in plasminogen activator inhibitor-1. Nature, 1992, 355, 270-273.	27.8	565
52	Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjugate Chemistry, 1992, 3, 138-146.	3.6	339
53	Preliminary x-ray analysis of crystals of plasminogen activator inhibitor-1. Proteins: Structure, Function and Bioinformatics, 1991, 9, 225-227.	2.6	6
54	Expression of human plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli as a soluble protein comprised of active and latent forms. Isolation and crystallization of latent PAI-1. BBA - Proteins and Proteomics, 1990, 1037, 16-23.	2.1	33

#	Article	IF	Citations
55	Fluorescence-based continuous assay for the aspartyl protease of human immunodeficiency virus-1. FEBS Letters, 1990, 262, 119-122.	2.8	22
56	X-ray analysis of HIV-1 proteinase at 2.7 Ã... resolution confirms structural homology among retroviral enzymes. Nature, 1989, 342, 299-302.	27.8	477
57	Crystallizable HIV-1 protease derived from expression of the viral pol gene in Escherichia coli. Biochemical and Biophysical Research Communications, 1989, 165, 1043-1050.	2.1	21
58	Chemical Modification of Proteins: An Overview. Advances in Chemistry Series, 1982, , 3-55.	0.6	41
59	ALTERNATIVE REDUCING AGENTS FOR REDUCTIVE METHYLATION OF AMINO GROUPS IN PROTEINS. International Journal of Peptide and Protein Research, 1981, 17, 345-352.	0.1	32
60	Reversible reductive alkylation of amino groups in proteins. Biochemistry, 1979, 18, 5392-5399.	2.5	48